1. Field of the Invention
The present invention is directed to piezoelectric stimulation of a predetermined body part, e.g., a nerve.
2. Description of Related Art
Nerve and muscle cells have membranes that are composed of lipids and proteins, and have unique properties of excitability such that an adequate disturbance of the cell's resting potential can trigger a sudden change in the membrane conductance. A neuronal process can be divided into unit lengths, which can be represented in an electrical equivalent circuit. Each unit length of the process is a circuit with its own membrane resistance, membrane capacitance and axonal resistance.
A nerve cell can be excited by increasing the electrical charge within the nerve, thus increasing the membrane potential inside the nerve with respect to the surrounding extracellular fluid. This fundamental feature of the nervous system i.e., its ability to generate and conduct electrical impulses, can take the form of action potentials (AP), which are a single electrical impulse passing down an axon. This action potential (nerve impulse or spike) is an “all or nothing” phenomenon. That is, once the threshold stimulus intensity is reached, an action potential will be generated.
Nerve stimulation may be realized by applying electrical pulses having different frequencies, amplitudes and waveforms. Stimulating electrical signals may be generated by electrodes disposed close to the target nerve or tissue of interest. Transcutaneous Electrical Nerve Stimulators (TENS) produce an electrical signal at frequencies up to approximately 200 Hz to stimulate nerves for relatively small periods of time. TENS use a small electrical device to deliver low frequency (10 Hz to 100 Hz) electrical impulses through the skin via electrode pads affixed to the skin. Electrodes are located at selected locations on the patient's skin and the electrical energy is transferred between the two electrodes. Electrical energy is generally applied in the form of low frequency electrical impulses. The impulses pass through the skin and interact with the nerves that lie beneath the skin. A typical TENS device includes a stimulator, lead wires and electrodes attached to the surface of the skin of the patient. The stimulator is an electrical pulse generator that delivers electrical pulses at a predetermined or selectable frequency. TENS devices are only effective in treating nerves very close to the surface of the skin because the low frequency electrical impulses diminish in strength very quickly due to tissue impedance and thus are not sufficient in intensity to stimulate nerves deep beneath the skin. As an alternative to surface electrodes, implantable electrodes may be surgically implanted proximate a target nerve or tissue of interest to be stimulated. The need for invasive surgery makes such implanted electrodes undesirable.
Aside from electrical stimulation, a nerve cell can also be excited by mechanical vibration which increases the membrane potential inside the nerve with respect to the surrounding extracellular fluid. This mechanical vibration or resonance can be detected by nerve endings if above a certain threshold frequency; that is, a minimum threshold level of stimuli is required before the action potential is triggered or fired. If the threshold stimulus intensity is reached an electrical signal is passed along the axon of the nerve and an action potential is fired.
PCT International Publication WO 2005/079909 discloses a method and apparatus for the detection and treatment of respiratory disorders using implanted devices to mechanically stimulate afferent nerves so as to indirectly cause an increase of the tone of upper airway muscles normally involved with maintenance of upper airway patency. The tone of the upper airway muscles typically decrease during Obstructive Sleep Apnea (OBS), contributing to a collapse and obstruction of the airway. During wakefulness reflexes work to maintain tone in upper airway muscles thereby preventing airway collapse. This reflex mechanism is substituted or enhanced during sleep to restore or maintain airway patency by the application of electrical or mechanical stimulation applied to the afferent nerves. In the case of mechanical stimulation a mechanical element, for example, a piezo-electric element, is implanted at a site in the vicinity of the upper airway, for example, within or adjacent to the base of the genioglossus muscle. A controller sends an electrical signal to the piezo-electric element thereby eliciting a vibration. Vibration of the element elicits stimulation of mechanoreceptor afferent nerve endings within the upper airway. The amplitude, frequency and duration of the mechanical stimulation are controlled such that sufficient stimulation of afferent nerves is achieved without sensory stimulation sufficient to cause arousal from sleep. The mechanical stimulation of afferent nerves would typically be achieved by a period of several seconds of vibration at frequencies in the range of 10-50 Hz, and is tuned to the frequency at which the target receptors are most sensitive. As is evident from the required low frequency range stimulus of 10-50 Hz, the electrical signal used to invoke the mechanical vibrations must inherently be produced by an implanted pulse generator. Otherwise, transcutaneous delivery of such a low frequency electrical signal generated by a non-invasive signal generator would not be sufficient in strength or intensity to trigger stimulation of the afferent nerve beneath the skin as most of the energy would be dissipated at the level of the skin. As noted above, such a pulse generator that generates only low frequency would require surgery to be implanted. It is therefore, desirable to develop a piezoelectric neurostimulator implanted in proximity to a nerve of interest and employing a non-invasive signal generator to cause electrical stimulation of the piezo element resulting in mechanical vibration/resonance of the piezo element thereby stimulating the nerve.
U.S. Patent Application Publication No. 2006/0167500 discloses a neurostimulator using an implanted piezo-electric chip as an electrode. The neurostimulator includes driving circuitry connected to an ultrasound transducer and at least one piezoelectric chip located proximate a nerve fiber. The ultrasound transducer is positioned to create a pressure wave that is incident on the piezoelectric chip. The excitation of the piezoelectric materials in the piezoelectric chip generates an electric current that can then be used to stimulate an action potential or inhibit the creation of an action potential in the nerve. Here a mechanical signal is transmitted through the skin and is converted to an electrical signal by the piezoelectric chip.
It is therefore desirable to develop a neurostimulator in which a high frequency electrical signal is generated externally and transmitted through the skin causing a mechanical disturbance in an implanted piezoelectric element disposed in proximity to a nerve of interest of sufficient intensity to cause firing of an action potential in the nerve.
An aspect of the present invention is directed to piezoelectric stimulation of a nerve of interest to invoke firing of an action potential by transcutaneously applying high frequency burst packets of electrical energy.
Another aspect of the present invention is directed to piezoelectric stimulation of a nerve of interest to invoke firing of an action potential by transcutaneously applying a continuous high frequency waveform.
Still another aspect of the present invention is directed to a stimulation device including an external non-implantable transmitting device powered by a power source and generating an electrical waveform signal. A surface electrode applies the generated electrical waveform signal transcutaneously An implantable piezoelectric element receives the applied electrical waveform signal generated transcutaneously and, in turn, causes mechanical deformation resulting in mechanical vibration of the implantable piezoelectric element sufficient to stimulate a predetermined body part such as the stimulation and firing of an action potential in a nerve.
Yet another aspect of the present invention is directed to a method for stimulating a predetermined body part such as a nerve using a device in accordance with the preceding paragraph. A piezoelectric element is implanted proximate the predetermined body part. An electrical waveform signal is generated using an external non-implantable transmitting device powered by a power source. The generated electrical waveform signal is applied transcutaneously through skin via a surface electrode. A piezoelectric element implanted proximate the predetermined body part receives the applied electrical waveform signal generated transcutaneously causing it mechanically to deform resulting in mechanical vibration of the piezoelectric element sufficient to stimulate the predetermined body part.
The foregoing and other features of the present invention will be more readily apparent from the following detailed description and drawings of illustrative embodiments of the invention wherein like reference numbers refer to similar elements throughout the several views and in which:
The present invention is directed to a neurostimulator for precise deep nerve stimulation from the surface of the skin in a minimally invasive manner. An exemplary neurostimulator 100 in accordance with the present invention is shown in
In one specific embodiment of a piezoelectric element adapted for use implantable in the human body, the piezoelectric element is made of a piece of quartz having a thickness of approximately 100 μm, a width of approximately 1 mm and a length of approximately 10 mm. A piezoelectric element of such dimensions may be implanted into a patient using a conventional 16 gauge needle. The dimensions of the piezoelectric element may be modified, as desired, depending on many factors such as its method of implantation into the body.
Piezoelectric element 125 may be surrounded by a housing 400 or cage as illustrated in greater detail in
In another embodiment, the expandable cage may be made of an absorbable material such as Ethisorb® (an absorbable synthetic composite made from polyglactin and polydioxanon) from Ethicon, Inc. of Somerville, N.J., or a combination of absorbable and non-absorbable materials. The absorbable material would preferably dissolve after a predetermined period of time so that the implantable piezoelectric element could be expelled from the body in a non-invasive manner.
As an alternative to the collapsible cage described above, the housing may have a stable structure rather than a collapsible structure that itself has an outer diameter (D) that is smaller than the diameter of an opening in the body to allow insertion therethrough, as shown in
During implantation of the piezoelectric element 125, the collapsible cage 400 is compressed and loaded into a single or multi-lumen catheter for delivery and placement at a desired nerve of interest. The catheter may be any catheter such as a Foley catheter. Fluroroscopy, ultrasound or other similar technology known to those skilled in the art may be used to aid in delivery and placement of the implantable piezoelectric element 125. If a multi-lumen catheter is used, other lumens may be used to provide an access for visualization, or monitor a physiological state of the body while placing the implantable piezoelectric element 125. An expulsion element such as a push rod or the like is inserted into the primary lumen behind, the housing 400 enclosing the piezoelectric element 125, and once the distal end of the catheter is properly positioned within the body, the expulsion element is moved toward the distal end of the catheter to thereby expel the piezoelectric element 125 enclosed in the housing 400 from the distal end of the catheter and into the body. As the implantable piezoelectric element 125 exits the catheter, the collapsible cage 400 is no longer restrained in its collapsed state, and automatically returns to its fully expanded state. Although use of a catheter is described, other suitable implantation methods may also be used, such as placement via, the working channel in a cystoscope or similar surgical tool, or placement via laparoscopic or open surgical methods. Once deployed within the body, the expandable cage is dimensioned to prevent the device from passing out from the body.
As mentioned above, alternate embodiments of the piezoelectric element 125 that do not employ a cage or housing may also be suitable, such as that shown in
Piezoelectric element 125 may be constructed using pieces of quartz of various sizes, as desired. The larger the volume of the piezoelectric element, the greater the vibration that can be generated. Selection of the material, structure and dimensions of the piezoelectric element is designed to achieve the desired resonance frequency required to stimulate the nerve of interest and trigger firing of an action potential. Application of an electrical field generated transcutaneously causes mechanical deformation (e.g., alternating stress) in the piezoelectric material causing it to vibrate or resonate. The vibration frequency is chosen to be the resonant frequency of the block, typically in the range of approximately 100 kHz to approximately 1 MHZ. The piezoelectric element vibrates/resonates mechanically due to the piezoelectric effect. The resulting vibration triggers an action potential either directly (piezo element in contact with the nerve) or indirectly (piezo element causes vibration of muscle/fat/fluid which encompasses nerve). Piezoelectric element 125 is designed so that it has a predetermined resonant frequency so as to trigger the firing of an action potential in the nerve of interest.
Nerves are stimulated and action potentials are generated by low frequency waveforms in the range of approximately 1 Hz-approximately 40 Hz. For example, the pudendal nerve is stimulated by a low frequency signal on the order of approximately 10 Hz-approximately 40 Hz. However, in order to stimulate such a nerve transdermally from the surface of the skin, an external signal generator must produce a high frequency waveform in the range of approximately 100 kHz-approximately 1 MHz in order to overcome the impedance of the skin and tissue so as to provide the necessary intensity of the stimulus to cause firing of the action potential for the nerve of interest. Such high frequency waveforms cannot be employed to directly stimulate a nerve since they do not respond to such high frequency signals.
Taking such competing constraints into consideration, an action potential may be triggered in a nerve of interest with the transmitting device 105 in
The modulated signal 306 is provided to an appropriate surface electrode 110, such as DURA-STICK Self Adhesive Electrodes from Chattanooga Group, Inc. of Hixson, Tenn., that applies the modulated waveform transcutaneously through the skin 115. Surface electrode 110 is depicted by a single block, however, it represents more than one physical structure, as shown in
The above-described signal transmission device 205 may further include a biofeedback mechanism to create a closed-loop system and provide a system wherein nerve stimulation is selective, that is, applied only when necessary as opposed to constantly. One or more biofeedback devices 235 are preferably implanted within the body. Each biofeedback device 235 preferably includes at least one sensor 240 for monitoring, detecting or sensing a parameter such as a bio-physiological property, and a data transmission device 245 that transmits data or information gathered by the sensor back outside the body to be further processed as described more fully below.
Transdermal signal transmission device 205 may include a microcontroller or microprocessor 255 and a receiving device 250 such as a MAX1472 from Maxim Semiconductors of Sunnyvale, Calif., that is electrically coupled to and powered by the power source 220. Data from one or more of the biofeedback devices 235 is received by receiving device 250 and transmitted to the microcontroller 255. Communication from the transmitter 245 to a receiver 250 is depicted in
Thus far a high frequency burst packet has been described as being produced by the transmitting device 105 using the transdermal signal transmission device 205 shown in
Signal transmitting device 605 in accordance with this second embodiment differs from the transdermal signal transmission device 205 of
This translation of energy from a high frequency to a low frequency signal may be achieved by restricting the resonance in only a single direction and is illustrated by way of the following example employing a cantilever.
Referring to equation (1) below, the frequency of an electric field equals the harmonic order (n) multiplied by the frequency constant (in one direction—assume in the vertical direction) of a material, divided by the thickness of a crystal, for example, quartz. The harmonic constant of quartz is 2870 kHz-mm. In order for the quartz crystal to be able to absorb the incoming resonance at 210 kHz the frequency has to be translated into a low frequency resonance of approximately 40 Hz, and requires that the movement be restricted to only the vertical direction with the length of the crystal much longer than its thickness. The specific dimensions of the crystal are calculated as follows:
FX=nkx/t [Equation 1]
where
Fx is the frequency of the electric field in one direction (in this case the x direction),
n is the harmonic order,
kx is the frequency constant in the x direction (in this case for quartz listed above), and
t is the thickness of the crystal.
Using our example of quartz and 210 kHz for the desired frequency of the electric field:
FX=(1)2870 kHz-mm/x=210 kHz,
where the harmonic order (n) is assumed to be 1 for fundamental mode, and x is the thickness of the crystal.
As stated above, assuming that the length is much longer than the thickness, for instance, the length is 100 times the thickness, solving the equation above would result in a crystal 1367 mm in length and 13.67 mm in thickness, or height. This size crystal can be used as a cantilever, or dampening element. The crystal may be scaled down to a more practical size for implantation into the human body such as a length of 10 mm and a width of 100 μm.
This example quartz crystal still needs to translate the high frequency into low frequency resonance so the nerve will be stimulated. Resonant frequency is defined as follows:
where
t is the thickness,
L is the length,
E is Young's Modulus, and
p is the density.
The Young's Modulus of quartz is 71.7 GPa, and the density of quartz is 2.66 g/cm3.
It is assumed that the cantilever will reach resonance when the base of the crystal moves at 210 kHz. In order to dampen that frequency so that the end of the cantilever will resonate at 40 Hz, a damping spring is used.
By using a spring with the correct spring constant, the resonant frequency is reduced from 210 kHz to 40 Hz, which is within a specified range required for triggering firing of an action potential.
It is to be noted that in either embodiment (e.g., high frequency burst packets or high frequency continuous waveform) the biofeedback device, microcontroller and receiver may be eliminated wherein the signal generated by the transmitting device remains continuous rather than being controlled or adjusted based on any feedback data.
Piezoelectric devices allow for specific targeting of a nerve to be stimulated. Moreover, if multiple piezoelectric devices are utilized, stimulation may be selective targeting one or more of the mechanical devices at different times. In addition, the use of multiple piezoelectric devices provides the enhanced flexibility of designing each device to have the same or different resonant frequencies, as desired. By way of example only, the present invention has been described with respect to stimulation of a nerve of interest, however, stimulation of any body part is contemplated and within the intended scope of the present invention.
Thus, while there have been shown, described, and pointed out fundamental novel features of the invention as applied to a preferred embodiment thereof, it will be understood that various omissions, substitutions, and changes in the form and details of the devices illustrated, and in their operation, may be made by those skilled in the art without departing from the spirit and scope of the invention. For example, it is expressly intended that all combinations of those elements and/or steps that perform substantially the same function, in substantially the same way, to achieve the same results be within the scope of the invention. Substitutions of elements from one described embodiment to another are also fully intended and contemplated. It is also to be understood that the drawings are not necessarily drawn to scale, but that they are merely conceptual in nature. It is the intention, therefore, to be limited only as indicated by the scope of the claims appended hereto.
Every issued patent, pending patent application, publication, journal article, book or any other reference cited herein is each incorporated by reference in their entirety.
This application is a continuation-in-part of U.S. patent application Ser. No. 11/146,522, now issued as U.S. Pat. No. 7,979,137, filed on Jun. 7, 2005, which is herein incorporated by reference in its entirety; and claims the benefit of U.S. Provisional Application No. 61/211,197, filed Mar. 27, 2009, which is herein incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3683915 | Voss | Aug 1972 | A |
3902502 | Liss et al. | Sep 1975 | A |
3933147 | DuVall et al. | Jan 1976 | A |
3941136 | Bucalo | Mar 1976 | A |
4406288 | Horwinski et al. | Sep 1983 | A |
4537195 | McDonnell | Aug 1985 | A |
4719922 | Padjen et al. | Jan 1988 | A |
4909255 | Farin | Mar 1990 | A |
4989605 | Rossen | Feb 1991 | A |
5167237 | Rabin et al. | Dec 1992 | A |
5350414 | Kolen | Sep 1994 | A |
5358514 | Schulman | Oct 1994 | A |
5421817 | Liss et al. | Jun 1995 | A |
5458630 | Hoegnelid et al. | Oct 1995 | A |
5464434 | Alt | Nov 1995 | A |
5476481 | Schondorf | Dec 1995 | A |
5487759 | Bastyr et al. | Jan 1996 | A |
5556421 | Prutchi et al. | Sep 1996 | A |
5558640 | Pfeiler et al. | Sep 1996 | A |
5562717 | Tippey et al. | Oct 1996 | A |
5617876 | van Duyl | Apr 1997 | A |
5645062 | Anderson et al. | Jul 1997 | A |
5702428 | Tippey et al. | Dec 1997 | A |
5722996 | Bonnet et al. | Mar 1998 | A |
5730125 | Prutchi et al. | Mar 1998 | A |
5735887 | Barreras, Sr. et al. | Apr 1998 | A |
5791344 | Schulman et al. | Aug 1998 | A |
5851223 | Liss et al. | Dec 1998 | A |
5902329 | Hoffmann et al. | May 1999 | A |
5984854 | Ishikawa et al. | Nov 1999 | A |
5993414 | Haller | Nov 1999 | A |
6035236 | Jarding et al. | Mar 2000 | A |
6092530 | Weissman et al. | Jul 2000 | A |
6099479 | Christopherson et al. | Aug 2000 | A |
6155267 | Nelson | Dec 2000 | A |
6164284 | Schulman et al. | Dec 2000 | A |
6167304 | Loos | Dec 2000 | A |
6183461 | Matsuura et al. | Feb 2001 | B1 |
6199575 | Widner | Mar 2001 | B1 |
6205359 | Boveja | Mar 2001 | B1 |
6221024 | Miesel | Apr 2001 | B1 |
6231516 | Keilman et al. | May 2001 | B1 |
6240317 | Villaseca et al. | May 2001 | B1 |
6263246 | Goedeke et al. | Jul 2001 | B1 |
6285897 | Kilcoyne et al. | Sep 2001 | B1 |
6298272 | Peterfeso et al. | Oct 2001 | B1 |
6330885 | Weissman et al. | Dec 2001 | B1 |
6354991 | Gross et al. | Mar 2002 | B1 |
6360129 | Ley et al. | Mar 2002 | B1 |
6366814 | Boveja et al. | Apr 2002 | B1 |
6377853 | Malaney et al. | Apr 2002 | B1 |
6384353 | Huang et al. | May 2002 | B1 |
6402689 | Scarantino et al. | Jun 2002 | B1 |
6404204 | Farruggia et al. | Jun 2002 | B1 |
6413393 | Van Antwerp et al. | Jul 2002 | B1 |
6432050 | Porat et al. | Aug 2002 | B1 |
6438407 | Ousdigian et al. | Aug 2002 | B1 |
6442413 | Silver | Aug 2002 | B1 |
6443883 | Ostrow et al. | Sep 2002 | B1 |
6447462 | Wallace et al. | Sep 2002 | B1 |
6459933 | Lurie et al. | Oct 2002 | B1 |
6471645 | Warkentin et al. | Oct 2002 | B1 |
6497655 | Linberg et al. | Dec 2002 | B1 |
6505074 | Boveja et al. | Jan 2003 | B2 |
6516227 | Meadows | Feb 2003 | B1 |
6535766 | Thompson et al. | Mar 2003 | B1 |
6560490 | Grill et al. | May 2003 | B2 |
6567706 | Bar-Or et al. | May 2003 | B2 |
6652449 | Gross et al. | Nov 2003 | B1 |
6662052 | Sarwal et al. | Dec 2003 | B1 |
6668191 | Boveja | Dec 2003 | B1 |
6701185 | Burnett et al. | Mar 2004 | B2 |
6712772 | Cohen et al. | Mar 2004 | B2 |
6751501 | Schuler et al. | Jun 2004 | B1 |
6836684 | Rijkhoff et al. | Dec 2004 | B1 |
6862480 | Cohen et al. | Mar 2005 | B2 |
6879859 | Boveja | Apr 2005 | B1 |
6907293 | Grill et al. | Jun 2005 | B2 |
7047078 | Boggs, II et al. | May 2006 | B2 |
7054690 | Imran | May 2006 | B2 |
7062330 | Boveja et al. | Jun 2006 | B1 |
7310557 | Maschino et al. | Dec 2007 | B2 |
7387603 | Gross et al. | Jun 2008 | B2 |
7427280 | Gerber | Sep 2008 | B2 |
7502652 | Gaunt et al. | Mar 2009 | B2 |
7599736 | DiLorenzo | Oct 2009 | B2 |
7676271 | Wahlstrand et al. | Mar 2010 | B2 |
7815895 | Katagiri et al. | Oct 2010 | B2 |
8170683 | Wahlgren | May 2012 | B2 |
20010018606 | Ingle et al. | Aug 2001 | A1 |
20010025137 | Webb et al. | Sep 2001 | A1 |
20010051768 | Schulman et al. | Dec 2001 | A1 |
20020001870 | Oda et al. | Jan 2002 | A1 |
20020011592 | Matsuo | Jan 2002 | A1 |
20020026141 | Houben et al. | Feb 2002 | A1 |
20020026244 | Trieu | Feb 2002 | A1 |
20020082480 | Riff et al. | Jun 2002 | A1 |
20020103514 | Abrahamson | Aug 2002 | A1 |
20020107540 | Whalen et al. | Aug 2002 | A1 |
20020111542 | Warkentin et al. | Aug 2002 | A1 |
20020133196 | Thompson | Sep 2002 | A1 |
20020151816 | Rich et al. | Oct 2002 | A1 |
20030004403 | Drinan et al. | Jan 2003 | A1 |
20030004553 | Grill et al. | Jan 2003 | A1 |
20030162021 | van Heerden et al. | Aug 2003 | A1 |
20030204224 | Torgerson et al. | Oct 2003 | A1 |
20030212305 | Anderson et al. | Nov 2003 | A1 |
20030220669 | Shealy | Nov 2003 | A1 |
20030233137 | Paul | Dec 2003 | A1 |
20040068203 | Gellman et al. | Apr 2004 | A1 |
20040236194 | Meyer | Nov 2004 | A1 |
20050177067 | Tracey et al. | Aug 2005 | A1 |
20050277998 | Tracey et al. | Dec 2005 | A1 |
20060047325 | Thimineur et al. | Mar 2006 | A1 |
20060095090 | De Ridder | May 2006 | A1 |
20060111756 | Chang | May 2006 | A1 |
20060167500 | Towe et al. | Jul 2006 | A1 |
20060178703 | Huston | Aug 2006 | A1 |
20060195146 | Tracey et al. | Aug 2006 | A1 |
20060195153 | DiUbaldi | Aug 2006 | A1 |
20060229688 | McClure | Oct 2006 | A1 |
20060247721 | Maschino | Nov 2006 | A1 |
20070162085 | DiLorenzo | Jul 2007 | A1 |
20070167990 | Mangrum et al. | Jul 2007 | A1 |
20070219606 | Moreci et al. | Sep 2007 | A1 |
20070233204 | Lima et al. | Oct 2007 | A1 |
20070260288 | Gross | Nov 2007 | A1 |
20080132962 | DiUbaldi et al. | Jun 2008 | A1 |
20080132969 | Bennett et al. | Jun 2008 | A1 |
20080147146 | Wahlgren et al. | Jun 2008 | A1 |
20080161874 | Bennett et al. | Jul 2008 | A1 |
20080293830 | Katagiri et al. | Nov 2008 | A1 |
20090005713 | Podrazhansky et al. | Jan 2009 | A1 |
20090048642 | Goroszeniuk | Feb 2009 | A1 |
20090054952 | Glukhovsky et al. | Feb 2009 | A1 |
20090062874 | Tracey et al. | Mar 2009 | A1 |
20090132018 | DiUbaldi et al. | May 2009 | A1 |
20090157149 | Wahlgren et al. | Jun 2009 | A1 |
20090187230 | Dilorenzo | Jul 2009 | A1 |
20100042018 | Kleinsinger | Feb 2010 | A1 |
20100042180 | Mueller et al. | Feb 2010 | A1 |
20100076533 | Dar et al. | Mar 2010 | A1 |
Number | Date | Country |
---|---|---|
1593683 | Mar 2005 | CN |
1745857 | Mar 2006 | CN |
10033400 | Jan 2001 | DE |
0783267 | Feb 1999 | EP |
1048264 | Nov 2000 | EP |
200316991 | Nov 2000 | JP |
2001-259047 | Sep 2001 | JP |
2003135607 | May 2003 | JP |
WO 9014127 | Nov 1990 | WO |
WO 9718856 | May 1997 | WO |
WO 9739796 | Oct 1997 | WO |
WO 9955411 | Nov 1999 | WO |
WO 0033738 | May 2000 | WO |
WO 0033065 | Jun 2000 | WO |
WO 0149369 | Jul 2001 | WO |
WO 0156633 | Aug 2001 | WO |
WO 0222008 | Mar 2002 | WO |
WO 0227294 | Apr 2002 | WO |
WO 02058551 | Aug 2002 | WO |
WO 02062215 | Aug 2002 | WO |
WO 03015625 | Feb 2003 | WO |
WO 03020364 | Mar 2003 | WO |
WO 03030733 | Apr 2003 | WO |
WO 03071944 | Sep 2003 | WO |
WO 2004050172 | Jun 2004 | WO |
WO 2005002663 | Jan 2005 | WO |
WO 2005079909 | Sep 2005 | WO |
WO 2007092301 | Aug 2007 | WO |
Entry |
---|
Reilly, J. Patrick, “Electrical Stimulation and Electropathology,” Cambridge University Press (1992); pp. 120-129; 190-205; 252-261; 308-325; 447-459. |
Copending, co-owned U.S. Appl. No. 60/543,722, filed Feb. 11, 2004. |
Copending, co-owned U.S. Appl. No. 11/043,830, filed Jan. 26, 2005. |
Copending, co-owned U.S. Appl. No. 11/146,522, filed Jun. 7, 2005. |
Copending, co-owned U.S. Appl. No. 11/343,627, filed Jan. 31, 2006. |
Copending, co-owned U.S. Appl. No. 12/661,949, filed Mar. 26, 2010. |
Copending, co-owned U.S. Appl. No. 11/344,825, filed Jan. 31, 2006. |
Copending, co-owned U.S. Appl. No. 13/094,644, filed Apr. 26, 2011. |
Copending, co-owned U.S. Appl. No. 61/211,197, filed Mar. 27, 2009. |
Beceker, T.J., “Cardio MEMS Moves Closer to Commercializing its Innovative Heart Sensors,” (Feb. 27, 2005) ATDC News & Information, Georgia Institute of Technology. |
Chappel, J., Electronic News—Ambient Intelligence (2002). |
Rousche, P.J. et al., “Flexible Polyimide-Based Intracortical Electrode ARrays with Bioactive Capacity,” IEEE Transactions on Biomedical Engineering, vol. 48, No. 3 (2001). |
Siwapornsathain, E. et al., “Telemetry and Sensor Platform for Ambulatory Urodynamics,” Proceedings 2nd Annual International IEEE-EMBS Special Topica Conference (May 2002). |
Voskerician, G. et al., “Biocompatiblity and Biofouling of MEMS Drug Delivery Devices,” Biomaterials, 24 (2003), pp. 1959-1967. |
Walter, et al., “Evaluation of a 316LVM Woven Eye Electrode for Direct Bladder Stimulation,” Engineering in Medicine and Biology Society 1991, vol. 13 (1991), pp. 1853-1854. |
Fiber Optic Sensors, Products Datasheet FOP—M Pressure Sensor (undated). |
Frost & Sullivan Report (2002). |
Rossell, J. et al., “Skin Impedance from 1 Hz to 1 MHz,” IEEE Transactions on Biomedical Engineering, vol. 35, No. 8, Aug. 1988. |
Reilly, J. Patrick, “Electrical Stimulation and Electropathology,” Cambridge University Press (1992). |
Junge, et al., “Titanium Coating of a Polypropylene Mesh for Hernia Repair: Effect on Biocompatibility,” Hernia, vol. 6, No. 9, pp. 115-119, pub'd on line Dec. 4, 2004. |
International Search Report dated Sep. 2, 2010 for International Application No. PCT/US2010/028690 (8 pages). |
English translation of Jun. 26, 2012 Office Action from Japanese Patent Office in counterpart Japanese Patent Application No. 2008-515738 (3 pages). |
Co-owned, copending U.S. Appl. No. 11/866,588, filed Oct. 3, 2007. |
Number | Date | Country | |
---|---|---|---|
20100249677 A1 | Sep 2010 | US |
Number | Date | Country | |
---|---|---|---|
61211197 | Mar 2009 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11146522 | Jun 2005 | US |
Child | 12661949 | US |